Surrozen, Inc.

Surrozen, Inc. is a biotechnology company specializing in the discovery and development of drug candidates that selectively modulate the Wnt pathway for tissue repair and regeneration. The company's focus is on developing tissue-specific antibodies with applications across various disease areas, including the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its pipeline includes SZN-043, a tissue-specific R-spondin mimetic for severe liver disease, and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to specific Frizzled and LRP receptors expressed in intestinal crypts.

Products

• Tissue-specific antibodies for tissue repair and regeneration